Magazine Article | June 1, 2023

From Biggest Pharma To Rare Disease Start-Up

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

Martin Mackay describes himself, with humility, as a very lucky man. But it takes a lot more than luck to rise from working-class roots to lead global R&D operations at Pfizer, AstraZeneca, and Alexion Pharmaceuticals. Mackay’s current venture, Rallybio, a rare disease company he cofounded in 2018 with former Alexion colleagues Stephen Uden and Jeffrey Fryer, gave him a turn in the CEO chair, and a chance to try his hand at building a drug company from scratch.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader